BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/Phoenix X-WR-TIMEZONE:America/Phoenix BEGIN:VEVENT UID:1469@azbio.org DTSTART;TZID=America/Phoenix:20200506T100000 DTEND;TZID=America/Phoenix:20200506T110000 DTSTAMP:20200430T130407Z URL:https://www.azbio.org/events/impacting-public-health-how-can-my-idea-b e-a-part-of-the-solution SUMMARY:Impacting Public Health: How Can My Idea Be A Part of the Solution? - Webinar - 6 May 20 10:00 DESCRIPTION:\nImpacting Public Health:\nHow Can My Idea Be A Part of the So lution?\nMay 6\, 2020\n1:00 pm–2:00 pm EDT \; | 10:00 am -11 am PDT/ AZ\nREGISTER\nJLABS Program Overview\nWhen a pandemic hits\, as a start-up company you may find that your technology can be aligned to help. However \, now your timeline is expedited with a global health emergency and you n eed to get your technology into the market. How do you start to connect wi th the right players to get your technology into the U.S. market to make a n impact on public health safety and security?\n\nJoin our discussion as w e bring together experts from federal agencies to discuss their views on s trategies for getting your product through the right agencies for approval and funding opportunities\, as well as insight from industry leaders who have already navigated this course.\n\nThis program is a product of a coll aboration between Johnson &\; Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA)\, a com ponent of the Office of the Assistant Secretary for Preparedness and Respo nse in the U.S. Department of Health and Human Services.\nSpeakers\nJames (Jim) R. Appleman\, Ph.D.\n\nSr. Vice-President\, R&\;D and Chief Scien tific Officer of Primmune Therapeutics\n\nJames (Jim) R. Appleman\, Ph.D. is Sr. Vice-President\, R&\;D and Chief Scientific Officer of Primmune Therapeutics\, a private pharmaceutical company which he co-founded and wh ere he is a member of the Board of Directors.\n\nOne continuous thread in Dr. Appleman’s career is his focus on treating serious diseases\, with p articular emphasis on respiratory and hepatic viral infections and cancer. Dr. Appleman’s first serious foray into immunotherapy was at Anadys Pha rmaceuticals where he personally led the ANA773 team from project concepti on through realization (characterization of target-mediated biology\, sele ction of medicinal chemistry starting points\, lead optimization\, candida te selection\, preclinical development\, culminating in clinical proof of concept). ANA773 is a novel TLR7 (toll-like receptor 7) agonist originally intended for the treatment of cancer and hepatic viral diseases. His expe rience with diverse TLR7 agonists and other activators of innate immunity in these two distinct therapeutic areas provided the foundation for the cr eation of Primmune and its current mission – to discovery and develop no vel immunotherapeutics for the treatment of cancer and serious viral disea ses like COVID-19.\n\nHe received a Ph.D. in biochemistry from Oklahoma St ate University and completed his postdoctoral training at Dartmouth Medica l School.\n\nChristopher P. Locher\, Ph.D.\n\nCo-founder and CEO of Versat ope Therapeutics\n\nChristopher Locher\, PhD is a co-founder and CEO of Ve rsatope Therapeutics\, a Lowell-based company focused on vaccine and thera peutic delivery. He was previously a Senior Director at Vertex Pharmaceuti cals where he was responsible for establishing external R&\;D programs. \n\nPrior to that\, he was the VP of Preclinical Development at Opsona The rapeutics in Dublin\, Ireland and helped build the team and pipeline with new products (biologics and new chemical entities). He has delivered on ma ny projects by coordinating the internal activities discovery teams with e xternal development teams\, key opinion leaders and biotechnology alliance s.\n\nCarla Cartwright\n\nSenior Director\, Global Digital and Regulatory Policy\, Johnson &\; Johnson\n\nCarla is a member of the Johnson &\; Johnson Government Affairs &\; Policy (GA&\;P) policy team where sh e manages a variety of global regulatory policy issues across the pharmace utical\, consumer and medical device sectors including importation\, harmo nization\, and biosimilars. Regularly convening and leading cross function al team on key issues\, Carla works regularly with partners in legal\, pri vacy\, regulatory affairs\, and supply chain. She leads on global policy i ssues related to digital and emerging technology for GA&\;P and is the co-lead of the Digital and Emerging Technology Platform Team.\n\nCarla was previously a part of the Federal Affairs team where she led on FDA matter s and supported the oncology and immunology portfolios and worked for Jans sen’s Global Regulatory Policy and Intelligence team where she was the U S policy lead on topics including clinical trial innovation\, patient enga gement\, expedited approval pathways\, disease interception\, and combinat ion products. Prior to joining Johnson &\; Johnson\, Carla was an attor ney and team leader in FDA's Office of the Chief Counsel where she advised the Center for Drug Evaluation and Research on legal and policy issues\, working closely with the Offices of Policy and Legislation.\n\nCarla is a graduate of Washington University in St. Louis and has a JD from Yale Law School and an LLM from Georgetown University Law Center.\n\nJonathan Seals \, Ph.D.\n\nDirector\, Strategic Science and Technology at Biomedical Adva nced Research and Development Authority (BARDA)\n\nDr. Seals is currently a Scientific Project Manager at BARDA in the Influenza and Emerging Diseas es Division. Dr. Seals earned his Ph.D. in Cell Biology from Washington Un iversity (MO) in 1979.\n\nFollowing a postdoctoral fellowship at Brown Uni versity in the Department of Physiological Chemistry\, he spent 7 years in Academia on the faculty in the Department of Biochemistry at the Universi ty of Massachusetts Medical School\, 20 years in Industry with several Bos ton-area Biopharmaceutical companies\, and the past 13 years at BARDA.\n\n He has filled in a number of roles at BARDA\, including serving as part of BARDA’s leadership team from 2008-16\, standing up and heading its Stra tegic Science and Technology Division\, and formulating and executing stra tegy for Influenza and EID preparedness through award and management of mu ltiple product development contracts. As one of BARDA’s longest-serving members\, he has thorough knowledge of its mission\, history\, and operati ons.\n\nDani Peters\n\nPresident\, Magnet Strategy Group\n\nDani Peters is President of Magnet Strategy Group\, a consulting firm that manages publi c affairs strategies in the United States and Canada.\n\nFor over 15 years \, Dani has supported organizations in developing successful federal fundi ng and advocacy strategies with a variety of agencies that include the U.S . Department of Health and Human Services\, Department of Defense\, Depart ment of Veterans Affairs\, among others.\n\nDani is a also the Co-Founder of Cross-Border Health\, a non-profit organization that fosters dialogue b etween Canada and the United States around common health priorities. In ad dition to operating Magnet Strategy Group\, Dani serves on the Industry Ad visory Board for Bloom Burton &\; Co.\, a healthcare investment advisor y firm in Toronto. She is also a Health Leader-in-Residence for the World Health Innovation Network (WIN)\, within the University of Windsor’s Ode tte School of Business.\n\nDani earned her undergraduate degree from McGil l University and a Master of Arts in International Trade Policy from the M iddlebury Institute for International Studies at Monterey.\n\nIlana Goldbe rg\, Ph.D.\n\nProgram Director\, National Institute of Biomedical Imaging and Bioengineering\, NIH\n\nDr. Ilana Goldberg joined NIBIB in 2019 as a A AAS Science &\; Technology Policy Fellow. She currently has oversight o f discovery and research grants with an emphasis on biophotonics. Dr. Gold berg earned her B.S. degree from Brandeis University in chemistry and bioc hemistry\, where she gained expertise in protein crystallography. She earn ed her Ph.D. degree from Georgetown University in solid state and analytic al chemistry where she focused on the crystal growth of secondary explosiv es. In 2005\, she was awarded a Fulbright Fellowship to study crystal engi neering\, polymorphism\, and co-crystallization of small molecules at Ben Gurion University in Be’er Sheva\, Israel.\n\nPrior to her current posit ion\, she was a project manager in Global Medical Excellence for AstraZene ca. Dr. Goldberg spent five years as senior scientist and project manager at the Johns Hopkins University Applied Physics Laboratory\, where she man aged multidisciplinary research projects for the Department of Homeland Se curity. Before that\, she was Postdoctoral Research Fellow at the Transpor tation Security Laboratory in Atlantic City\, New Jersey\, where she focus ed on the development of thermal analysis methods for energetic materials as well as the advancement of explosive detection technologies.\n\nDr. Gol dberg is committed to supporting the development of technologies that engi neer the interactions between biological molecules and light to enhance th e landscape of bioengineered technologies.\nAgenda\n1:00 pm - Introduction s\n\n1:05 pm - \;Panel Presentations\n\n1:30 pm - \;Moderated Q&am p\;A\n\n1:45 pm - \;Audience Q&\;A\n\n2:00pm - \;Webinar Ends\n \n \; LOCATION:Webinar\, Anywhere\, USA\, United States X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Anywhere\, USA\, United Sta tes;X-APPLE-RADIUS=100;X-TITLE=Webinar:geo:0,0 END:VEVENT BEGIN:VTIMEZONE TZID:America/Phoenix X-LIC-LOCATION:America/Phoenix BEGIN:STANDARD DTSTART:20190507T100000 TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST END:STANDARD END:VTIMEZONE END:VCALENDAR